First Time Loading...

Progenity Inc
NASDAQ:PROG

Watchlist Manager
Progenity Inc Logo
Progenity Inc
NASDAQ:PROG
Watchlist
Price: 0.69 USD 0.01% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

PROG price has not been updated for more than 6 months. This may indicate that the stock has been delisted.

Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of PROG.

Key Points:
PROG Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

Financials

Balance Sheet Decomposition
Progenity Inc

Current Assets 75m
Cash & Short-Term Investments 67.2m
Other Current Assets 7.8m
Non-Current Assets 11.7m
PP&E 5.3m
Other Non-Current Assets 6.4m
Current Liabilities 46.7m
Accounts Payable 5.4m
Accrued Liabilities 29m
Other Current Liabilities 12.4m
Non-Current Liabilities 133.2m
Long-Term Debt 126.7m
Other Non-Current Liabilities 6.5m
Efficiency

Earnings Waterfall
Progenity Inc

Revenue
1.2m USD
Operating Expenses
-107.5m USD
Operating Income
-106.3m USD
Other Expenses
-122.7m USD
Net Income
-229m USD

Free Cash Flow Analysis
Progenity Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

PROG Profitability Score
Profitability Due Diligence

Progenity Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

41/100
Profitability
Score

Progenity Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

PROG Solvency Score
Solvency Due Diligence

Progenity Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
33/100
Solvency
Score

Progenity Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PROG Price Targets Summary
Progenity Inc

There are no price targets for PROG.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

PROG Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

PROG Price
Progenity Inc

1M 1M
-
6M 6M
-
1Y 1Y
-
3Y 3Y
-85%
5Y 5Y
-95%
10Y 10Y
-95%
Annual Price Range
0.69
52w Low
N/A
52w High
N/A
Price Metrics
Average Annual Return -60.21%
Standard Deviation of Annual Returns
N/A
Max Drawdown -96%
Shares Statistics
Market Capitalization 127.1m USD
Shares Outstanding 184 200 000
Percentage of Shares Shorted 14.04%

PROG Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Progenity Inc Logo
Progenity Inc

Country

United States of America

Industry

Health Care

Market Cap

127.1m USD

Dividend Yield

0%

Description

Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 124 full-time employees. The company went IPO on 2020-06-19. The firm is engaged in developing and commercializing molecular testing products in the fields of women's health, gastrointestinal health and oral biotherapeutics. The company applies multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to its molecular testing products and to the development of a suite of investigational ingestible devices and drug/device combinations designed to provide precise diagnostic sampling and drug delivery solutions. The Company’s molecular tests are: Innatal Prenatal Screen, Preparent Carrier Test, Riscover Hereditary Cancer Test, and Resura Prenatal Test for Monogenic Disease. The firm is also developing its pipeline products, such as Preecludia pre-eclampsia rule-out test, Drug Delivery System (DDS) platform, and Oral Biopharmaceutical Delivery System (OBDS). The company is also developing an ingestible capsule platform designed to help diagnose and treat gastrointestinal (GI) disorders.

Contact

CALIFORNIA
San Diego
4330 La Jolla Village Dr Ste 200
+18552932639.0
https://www.progenity.com/

IPO

2020-06-19

Employees

124

Officers

Chief Financial Officer
Mr. Eric d'Esparbes
CEO & Director
Mr. Aditya P. Mohanty
VP of Fin. & Accounting & Treasurer
Eric Fox
Chief Information Officer
Mr. Troy Seelye
Sr. VP, Gen. Counsel & Sec.
Mr. Clarke Neumann
Sr. VP of Sales
Mr. George Gianakopoulos
Show More
VP of HR
Ms. Robyn Hatton
Chief Commercial Officer
Mr. Sami Shihabi M.B.A., M.S.
Sr. VP of Strategic Operations
Mr. Kevin Howe Ph.D.
Head of Research
Dr. Sharat Singh Ph.D.
Show Less

See Also

Discover More